<html><head></head><body><h1>Tafasitamab-cxix</h1><p class="drug-subtitle"><b>Class:</b> Antineoplastic Agents<br/>
<b>Brands:</b> Monjuvi</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Patient advice</li>
<li>Preparations</li></ul><h2>Introduction</h2><p>Tafasitamab-cxix is an antineoplastic agent.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for Tafasitamab-cxix</h2><h3>Tafasitamab-cxix has the following uses:</h3><p>Tafasitamab-cxix is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Tafasitamab-cxix Dosage and Administration</h2><h3>General</h3><p>Tafasitamab-cxix is available in the following dosage form(s) and strength(s):</p><p>For injection: 200 mg of tafasitamab-cxix as lyophilized powder in single-dose vial for reconstitution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p><b>It is</b> <i>essential</i> <b>that the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:</b></p><ul>
<li>
<p>Administer premedications prior to starting tafasitamab-cxix.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>The recommended dosage of tafasitamab-cxix is 12 mg/kg as an intravenous infusion according to the following dosing schedule:</p>
<p>Cycle 1: Days 1, 4, 8, 15 and 22 of the 28-day cycle.</p>
<p>Cycles 2 and 3: Days 1, 8, 15 and 22 of each 28-day cycle.</p>
<p>Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Administer tafasitamab-cxix in combination with lenalidomide for a maximum of 12 cycles and then continue tafasitamab-cxix as monotherapy until disease progression or unacceptable toxicity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>See Full Prescribing Information for instructions on preparation and administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Administer premedications prior to starting tafasitamab-cxix.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>The recommended dosage of tafasitamab-cxix is 12 mg/kg as an intravenous infusion according to the following dosing schedule:</p><p>Cycle 1: Days 1, 4, 8, 15 and 22 of the 28-day cycle.</p><p>Cycles 2 and 3: Days 1, 8, 15 and 22 of each 28-day cycle.</p><p>Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer tafasitamab-cxix in combination with lenalidomide for a maximum of 12 cycles and then continue tafasitamab-cxix as monotherapy until disease progression or unacceptable toxicity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>See Full Prescribing Information for instructions on preparation and administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Tafasitamab-cxix</h2><h3>Contraindications</h3><p>None.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>Tafasitamab-cxix can cause infusion-related reactions. In the principal efficacy study (L-MIND), infusion-related reactions occurred in 6% of the 81 patients. Eighty percent of infusion-related reactions occurred during cycle 1 or 2. Signs and symptoms included chills, flushing, dyspnea, and hypertension. These reactions were managed with temporary interruption of the infusion and/or with supportive medication.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Premedicate patients prior to starting tafasitamab-cxix infusion. Monitor patients frequently during infusion. Based on the severity of the infusion-related reaction, interrupt or discontinue tafasitamab-cxix. Institute appropriate medical management.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Tafasitamab-cxix can cause serious or severe myelosuppression, including neutropenia, thrombocytopenia, and anemia. In L-MIND, Grade 3 neutropenia occurred in 25% of patients, thrombocytopenia in 12% and anemia in 7%. Grade 4 neutropenia occurred in 25% and thrombocytopenia in 6%. Neutropenia led to treatment discontinuation in 3.7% of patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor CBC prior to administration of each treatment cycle and throughout treatment. Monitor patients with neutropenia for signs of infection. Consider granulocyte colony stimulating factor administration. Withhold tafasitamab-cxix based on the severity of the adverse reaction. Refer to the lenalidomide prescribing information for dosage modifications of lenalidomide.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Fatal and serious infections, including opportunistic infections, occurred in patients during treatment with tafasitamab-cxix and following the last dose. &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In L-MIND, 73% of the 81 patients developed an infection. The most frequent infections were respiratory tract infection (24%), urinary tract infection (17%), bronchitis (16%), nasopharyngitis (10%) and pneumonia (10%). Grade 3 or higher infection occurred in 30% of the 81 patients. The most frequent grade 3 or higher infection was pneumonia (7%). Infection-related deaths were reported in 2.5% of the 81 patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor patients for signs and symptoms of infection and manage infections as appropriate.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Based on its mechanism of action, tafasitamab-cxix may cause fetal B-cell depletion when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with tafasitamab-cxix and for at least 3 months after the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Tafasitamab-cxix is initially administered in combination with lenalidomide. The combination of tafasitamab-cxix with lenalidomide is contraindicated in pregnant women, because lenalidomide can cause birth defects and death of the unborn child. Refer to the lenalidomide prescribing information on use during pregnancy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p><i>Risk Summary:</i> Based on its mechanism of action, tafasitamab-cxix may cause fetal B-cell depletion when administered to a pregnant woman. There are no available data on tafasitamab-cxix use in pregnant women to evaluate for a drug-associated risk. Animal reproductive toxicity studies have not been conducted with tafasitamab-cxix.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Tafasitamab-cxix is administered in combination with lenalidomide for up to 12 cycles. Lenalidomide can cause embryo-fetal harm and is contraindicated for use in pregnancy. Refer to the lenalidomide prescribing information for additional information. Lenalidomide is only available through a REMS program.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p><i>Clinical Considerations:</i> Immunoglobulin G (IgG) monoclonal antibodies are transferred across the placenta. Based on its mechanism of action, tafasitamab-cxix may cause depletion of fetal CD19 positive immune cells. Defer administering live vaccines to neonates and infants exposed to tafasitamab-cxix in utero until a hematology evaluation is completed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p><i>Animal Data:</i> Animal reproductive studies have not been conducted with tafasitamab-cxix. Tafasitamab-cxix is an IgG antibody and thus has the potential to cross the placental barrier permitting direct fetal exposure and depleting fetal B lymphocytes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p><i>Risk Summary:</i> There are no data on the presence of tafasitamab-cxix in human milk or the effects on the breastfed child or milk production. Maternal immunoglobulin G is known to be present in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed infant to tafasitamab-cxix are unknown. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with tafasitamab-cxix and for at least 3 months after the last dose. Refer to lenalidomide prescribing information for additional information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Tafasitamab-cxix can cause fetal B-cell depletion when administered to a pregnant woman. &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Refer to the prescribing information for lenalidomide for pregnancy testing requirements prior to initiating the combination of tafasitamab-cxix with lenalidomide.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise females of reproductive potential to use effective contraception during treatment with tafasitamab-cxix and for at least 3 months after the last dose. Additionally, refer to the lenalidomide prescribing information for additional recommendations for contraception.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Refer to the lenalidomide prescribing information for recommendations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>The safety and effectiveness of tafasitamab-cxix in pediatric patients have not been established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Among 81 patients who received tafasitamab-cxix and lenalidomide in L-MIND, 72% were 65 years and older, while 38% were 75 years and older. Clinical studies of tafasitamab-cxix did not include sufficient numbers of patients aged 65 and older to determine whether effectiveness differs compared to that of younger subjects. Patients 65 years and older had more serious adverse reactions (57%) than younger patients (39%). &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Common Adverse Effects</h3><p>The most common adverse reactions (≥20%) are neutropenia, fatigue, anemia, diarrhea, thrombocytopenia, cough, pyrexia, peripheral edema, respiratory tract infection, and decreased appetite.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Drug Interactions</h2><h3>Specific Drugs</h3><p><b>It is</b> <i>essential</i> <b>that the manufacturer's labeling be consulted for more detailed information on interactions with this drug, including possible dosage adjustments. Interaction highlights:</b></p><p>Please see product labeling for drug interaction information.</p><h2>Actions</h2><h3>Mechanism of Action</h3><p>Tafasitamab-cxix is an Fc-modified monoclonal antibody that binds to CD19 antigen expressed on the surface of pre-B and mature B lymphocytes and on several B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Upon binding to CD19, tafasitamab-cxix mediates B-cell lysis through apoptosis and immune effector mechanisms, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In studies conducted in vitro in DLBCL tumor cells, tafasitamab-cxix in combination with lenalidomide resulted in increased ADCC activity compared to tafasitamab-cxix or lenalidomide alone.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><p>Advise the patient to read the FDA-approved patient labeling (Patient Information).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Infusion-Related Reactions</h3><p>Advise patients to contact their healthcare provider if they experience signs and symptoms of infusion-related reactions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Myelosuppression</h3><p>Inform patients about the risk of myelosuppression. Advise patients to immediately contact their healthcare provider for a fever of 100.4°F (38°C) or greater or signs or symptoms of bruising or bleeding. Advise patients of the need for periodic monitoring of blood counts.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Infections</h3><p>Inform patients about the risk of infections. Advise patients to immediately contact their healthcare provider for a fever of 100.4°F (38°C) or greater or signs or symptoms of infection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Embryo-Fetal Toxicity</h3><p>Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy. &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise females of reproductive potential to use effective contraception during treatment with tafasitamab-cxix and for at least 3 months after the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise patients that lenalidomide has the potential to cause fetal harm and has specific requirements regarding contraception, pregnancy testing, blood and sperm donation, and transmission in sperm. Lenalidomide is only available through a REMS program.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Lactation</h3><p>Advise women not to breastfeed during treatment with tafasitamab-cxix and for at least 3 months after the last dose. &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Additional Information</h2><p>AHFS<i>first</i>Release<sup>™</sup>. For additional information until a more detailed monograph is developed and published, the manufacturer's labeling should be consulted. It is <i>essential</i> that the manufacturer's labeling be consulted for more detailed information on usual uses, dosage and administration, cautions, precautions, contraindications, potential drug interactions, laboratory test interferences, and acute toxicity.</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>For injection, for IV infusion only</p><p>200 mg</p><p>Monjuvi<sup></sup></p><p>MorphoSys US Inc.</p><p>AHFS Drug Information<sup></sup>. © Copyright 2021, Selected Revisions August 17, 2020. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><h2>References</h2><p>1. MorphoSys US Inc. MONJUVI<sup></sup> (tafasitamab-cxix) INTRAVENOUS prescribing information. 2020 Jul. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec13ac6b-bfde-4e84-907a-83bd69584d95</p><h2>More about tafasitamab</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: miscellaneous antineoplastics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Tafasitamab-cxix Intravenous &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Diffuse Large B-Cell Lymphoma</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>